Itamar Borochov - Cannabics Pharmaceuticals Co-Founder, CEO and Director
| CNBX Stock | USD 0.01 0 20.00% |
CEO
Mr. Itamar Borochov is Chief Executive Officer, Director of Cannabics Pharmaceuticals Inc. He is a cofounder of Cannabics Inc. and is its Chief Marketing Officer. Mr. Borochov is a known environmentalist with experience as an entrepreneur in the fields of organic agricultural and medical botanicals and brings vast expertise in the areas of market intelligence and organizational branding. since 2015.
| Age | 56 |
| Tenure | 9 years |
| Phone | 877 424 2429 |
| Web | https://www.cnbxpharma.com |
Cannabics Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.0031) % which means that it has lost $1.0031 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (42.8936) %, meaning that it created substantial loss on money invested by shareholders. Cannabics Pharmaceuticals' management efficiency ratios could be used to measure how well Cannabics Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -42.89 | |||
| Return On Asset | -1.0 |
Cannabics Pharmaceuticals Leadership Team
Elected by the shareholders, the Cannabics Pharmaceuticals' board of directors comprises two types of representatives: Cannabics Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cannabics. The board's role is to monitor Cannabics Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cannabics Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cannabics Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Gabriel Yariv, COO Pres | ||
| Tal Mofkadi, Financial Board | ||
| Uri BenOr, CFO | ||
| Dov Weinberg, CFO | ||
| Eran Ballan, Independent Director | ||
| Ilya MD, Head Devel | ||
| Yasha Borstein, Chief Data Officer | ||
| Yaakov Waksman, Head Research | ||
| Eyal Barad, COO, Director | ||
| Eyal Ballan, CTO and Director | ||
| Itamar Borochov, Co-Founder, CEO and Director | ||
| Ehud Rieger, Director | ||
| Shay Sarid, Co-Founder and Director | ||
| Sanja Goldberg, Chief Officer | ||
| Sigalit ArielyPortnoy, Validation Regulation | ||
| Estery GilozRan, Independent Director | ||
| Noam Permont, VP Relations |
Cannabics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cannabics Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -42.89 | |||
| Return On Asset | -1.0 | |||
| Current Valuation | 6.67 M | |||
| Shares Outstanding | 1.26 M | |||
| Shares Owned By Insiders | 57.59 % | |||
| Price To Earning | 31.09 X | |||
| Price To Book | 20.39 X | |||
| Price To Sales | 7,566 X | |||
| Gross Profit | 7.16 K | |||
| EBITDA | (3.52 M) |
Pair Trading with Cannabics Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cannabics Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cannabics Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Cannabics Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cannabics Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cannabics Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cannabics Pharmaceuticals to buy it.
The correlation of Cannabics Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cannabics Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cannabics Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cannabics Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cannabics Pharmaceuticals. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Cannabics Pharmaceuticals information on this page should be used as a complementary analysis to other Cannabics Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Cannabics OTC Stock analysis
When running Cannabics Pharmaceuticals' price analysis, check to measure Cannabics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannabics Pharmaceuticals is operating at the current time. Most of Cannabics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cannabics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannabics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cannabics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |